Indoco Remedies executed an agreement to sell its ophthalmic business to Sunways India for ₹110 crore on a slump sale basis.
The division contributed ₹47.79 crore (3.2%) to standalone revenue in FY25 and the sale is part of a strategy to focus on core therapeutic areas.
The transaction is expected to complete in about three months, pending fulfilment of conditions precedent, and is not a related party transaction.